


SARDA, KRISH Patient ID 33008	SARDA, KRISHNAKANT Patient ID 33008				Tabular Summary	Summary					LOREA HEALTHCARE PVT LTD	ГГТ
09.07.2022							BRUCE: Max HR: Max BP: Maximum	BRUCE: Total Exercise Time 07:09 Max HR: 150 bpm 81% of max predicted 18: Max BP: 140/90 mmHg BP at rest: 110/75 Maximum Workload: 6.60 METS	Time 07: of max p BP at re	09 redicted 184 st: 110/75	BRUCE: Total Exercise Time 07:09 Max HR: 150 bpm 81% of max predicted 184 bpm HR at rest: 97 Max BP: 140/90 mmHg BP at rest: 110/75 Max RPP: 18720 mmHg*bpm Maximum Workload: 6.60 METS	P
	Test Reason: Medical Histo	Test Reason: Screening for CAD Medical History: NO HISTORY.	CAD)RY.				Arrhythmia: A:48	-0.05 mV, 0.0 ia: A:48	0 mV/s in	III; EXER(Max. ST: -0.05 mV, 0.00 mV/s in III; EXERCISE STAGE 3 06:29 Arrhythmia: A:48	
	Ref. MD: O	rdering MD:					Reasons 1	Reasons for Termination: Fatigue	pm on: Fatigu	0		
	Technician: R	Technician: RUPALI Test Type: Treadmill Stress Test	Type: Treadn	ill Stress Te	sst		Summary	r: Resting ECG	: normal.	Functional	Summary: Resting ECG: normal. Functional Capacity: normal. HR Response to	
	Comment:						Exercise:	appropriate. B.	P Respons	e to Exercis	Exercise: appropriate. BP Response to Exercise: normal resting BP - appropriate	
							impression	impression: Normal stress test.	s test.	ullillas. Ilol	impression: Normal stress test.	
							Conclusic	Conclusion: GOOD EFFORT TOLERANCE ACHIEVED 81 % THR ON RX.	ORT TO	LERANCE		
							NORMAI NO SIGN	NORMAL BP RESPONSE NO SIGNIFICANT ST-T CI	SECHANG	ES NOTED	NORMAL BP RESPONSE NO SIGNIFICANT ST-T CHANGES NOTED FOR THE GIVEN WORKLOAD	
							STRESS	EST IS NEGA	TIVE FO	R INDUCI	STRESS TEST IS NEGATIVE FOR INDUCIBLE ISCHEMIA	
							DR. RAID MD, DM-C, MMC 2000	DR. RAIDATT DEORE MD, DM-CARDIOLOGIST MMC 2005(03/1520	ST			
Phase Name	Stage Name	Time in Stage	Speed (km/h)	Grade (%)	Workload (METS)	HR (bpm)	BP (mmHg)	RPP (mmHg*bpm	VE (/min)	ST Level (III mV)	Comment	
PRETEST	SUPINE	00:25	0.00	0.00	1.0	93	110/75	10230	0	-0.04		
	STANDING	00:21	0.00	00.00	1.0	85			0	-0.06		
FXFRCISE	HYPERV.	01:30	0.00	0.00	1.0	96	110/75	10560	0	-0.04		
	STAGE 2	03:00	2.50	12.00	5.7 4.7	139	120/88	18070	00	-0.03		
	STAGE 3	01:10	3.40	14.00	9.9	148	130/90	19240	0	-0.05		0
RECOVERY		02:53	0.00	0.00	1.0	94	140/90	13160	0	-0.02		
	*											
GE CardioSoft V6.61 (2)	V6.61 (2)			Unco	Unconfirmed							
								Attending MD:	ig MD:		1,	Page 1







PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

Company Name

: BANK OF BARODA

Reporting Date & Time : 09/07/2022 02:05 PM

• 09/07/2022 02:10 PM

Referred By : Dr.HOSPITAL	L PATIENT	Print Date 8	k Time : 09/07/2022 02:10 PN
PARAMETER NAME	RESULT VALUE	UNIT	NORMAL VALUES
	BIO	CHEMISTRY	
BSL-F & PP			
Blood Sugar Level Fasting	: 94	MG/DL	60 - 110
Blood Sugar Level PP	: 97	MG/DL	70 - 140
CALCIUM			
CALCIUM (serum)	: 9.40	MG/DL	8.4 - 10.4
RFT (RENAL FUNCTION TE	ST)		
BIOCHEMICAL EXAMINATIO			
UREA (serum)	_ : 28	MG/DL	0 - 45
UREA NITROGEN (serum)	: 13.08	MG/DL	√ - 21
CREATININE (serum)	: 0.9	MG/DL	0.5 - 1.5
URIC ACID (serum)	: 6.7	MG/DL	Male: 3.4 - 7.0
SEDIIM EI ECTROL VIES			Female : 2.4 - 5.7
SERUM ELECTROLYTES			
SERUM SODIUM	: 139	mEq/L	136 - 149

END OF REPORT

4.5

: 101

mEq/L

mEq/L

Technician

SERUM POTASSIUM

SERUM CHLORIDE

Report Type By:- PRITAM WAGHMARE

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)

3.8 - 5.2

98 - 107



(For Report Purpose Only)

Caring Redefine

PRN

: 081720

Patient Name

: Mr. SARDA KRISHNAKANT

Lab No

Age/Sex

: 36Yr(s)/Male

Req.No

: 4105 : 4105

Company Name

Collection Date & Time: 09/07/2022 1

Referred By

: BANK OF BARODA

Reporting Date & Time **Print Date & Time**

: 09/07/2022 02

PARAMETER NAME

: Dr.HOSPITAL PATIENT

UNIT

: 09/07/2022 0

RESULT VALUE

NORMAL VALUES

HAEMATOLOGY

BLOOD GROUP

BLOOD GROUP

RH FACTOR

"B"

POSITIVE

NOTE

This is for your information. No transfusion / therapeutic intervention is done without confirmation of blood group by concerned authorities. In case of infants less than 6 months, suggested to repeat Blood Group after 6 months of age for confirmation. Kindly confirm the Negative Blood Group by reverse blood grouping (Tube method).

END OF REPORT

Technician

Report Type By :-PRITAM WAGHMARE

Dr. POONAM KADAM

MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)





PRN

: 081720

Patient Name

: Mr. SARDA KRISHNAKANT

Age/Sex

PARAMETER NAME

: 36Yr(s)/Male

Company Name

: BANK OF BARODA

Referred By

: Dr.HOSPITAL PATIENT

Lab No

Req.No

: 4105 : 4105

Collection Date & Time: 09/07/2022 10:29 AM

Reporting Date & Time : 09/07/2022 02:05 PM

Print Date & Time

: 09/07/2022 02:09 PM

RESULT	VALUE

UNIT

NORMAL VALUES

HAEMATOLOGY

<u>HAEMOGRAM</u>				
HAEMOGLOBIN (Hb)	:	15.0	GM/DL .	Male: 13.5 - 18.0
PCV	:	47.1	%	Female : 11.5 - 16.5 Male : 40 - 54
RBC COUNT	:	5.34	Million/cu mm	Female: 37 - 47 Male: 4.5 - 6.5
M.C.V	:	88.2	cu micron	Female : 3.9 - 5.6 76 - 96
M.C.H.	:	28.1	pg	27 - 32
M.C.H.C	:	31.8	picograms	32 - 36
RDW-CV	:	11.9	%	11 - 16
WBC TOTAL COUNT	:	5560	/cumm	ADULT: 4000 - 11000 CHILD 1-7 DAYS: 8000 - 18000 CHILD 8-14 DAYS: 7800 - 16000 CHILD 1MONTH-<1YR: 4000 -
PLATELET COUNT WBC DIFFERENTIAL COUNT	:	263000	cumm	10000 150000 - 450000
NEUTROPHILS	:	52	%	ADIU T . 40 . 70
150011154	•	52	70	ADULT: 40 - 70 CHILD:: 20 - 40
ABSOLUTÉ NEUTROPHILS	:	2891.20	μL	2000 - 7000
LYMPHOCYTES	:	37	%	ADULT : 20 - 40
ABSOLUTE LYMPHOCYTES	:	2057.20	μL	CHILD:: 40 - 70 1000 - 3000
EOSINOPHILS	:	03	%	01 - 04
ABSOLUTE EOSINOPHILS	:	166.80	μL	20 - 500
MONOCYTES	:	08	%	02 - 08
ABSOLUTE MONOCYTES	:	444.80	μL	200 - 1000
BASOPHILS	:	00	%	00 - 01
ABSOLUTE BASOPHILS	:	0	μL	0 - 100

Technician

Report Type By :-PRITAM WAGHMARE

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)





PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

Company Name

: BANK OF BARODA

Reporting Date & Time

: 09/07/2022 02:05 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:09 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

RBC MORPHOLOGY

Normocytic Normochromic

WBC MORPHOLOGY

Within Normal Limits

PLATELETS

Adequate

PARASITES

Not Detected

Method: Processed on 5 Part Fully Automated Blood Cell Counter - sysmex XS-800i.

ESR

ESR MM (AT The End of 1 Hr.) By : 05

mm/hr

Male: 0 - 15

Westergren Method

Female: 0 - 20

END OF REPORT

Technician

PRITAM WAGHMARE Report Type By :-

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)
Pathologist





PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

Company Name

: BANK OF BARODA

Reporting Date & Time

: 09/07/2022 02:05 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:10 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

BIOCHEMISTRY

HbA1C- GLYCOSYLATED -HB

HBA1C

5.53

Normal Control:: 4.2 - 6.2 Good Control:: 5.5 - 6.7

Fair Control:: 6.8 - 7.6 Poor Control::>7.6

Instrument: COBAS C 111

The HbA1C determination is based on turbidimetric inhibition immunoassay (TNIA) for hemolysed whole blood on Cobas c111 system.

NOTE:

The HbA1C test shows your average blood sugar for last 3 months.

2. The HbA1C test does not replace your day-to-day monitoring of blood glucose. Use this test result along with your daily test results to measure yoir overall diabetes control.

How does HbA1C works?

The HbA1C test measures the amount of sugar that attaches to protein in your red blood cells. RBCs live for about 3 months, so this test shows your average blood sugar levels during that time. Greater the level of sugar & longer it is high, the more sugar that will attach to RBCs.

Why is this test so important?

Research studies demonstrated that the closer to normal your HbA1C level was, the less likely your risk of developing the long-term complications of diabetes. Such problems include eye disease and kidney problems.

Who should have the HbA1c test done?

Everyone with diabetes can benefit from taking this test. Knowing your HbA1C level helps you and your doctor decide if you need to change your diabetes management plan.

How often should you have a HbA1C test?

You should have this test done when you are first diagnosed with diabetes.

Then at least twice a year if your treatment goals are being met & blood glucose control is stable.

More frequent HbA1C testing (4 times / year) is recommended if your blood glucose management goals.

END OF REPORT

Dr. POONAM KADAM

MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)

PRITAM WAGHMARE Report Type By :-

Technician





PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

Company Name

: BANK OF BARODA

Reporting Date & Time : 09/07/2022 02:05 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:11 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

BIOCHEMISTRY

LET /	1 :	function	Toet \
	Liver	Tunction	1621

BILIRUBIN TOTAL (serum) BILIRUBIN INDIRECT (serum) BILIRUBIN INDIRECT (serum) S.G.O.T (serum)	:	0.7 0.3 0.40 37	MG/DL MG/DL MG/DL IU/L	•	INFANTS: 1.2 - 12.0 ADULT:: 0.1 - 1.2 ADULT & INFANTS: 0.0 - 0.4 0.0 - 1.0 5 - 40
S.G.P.T (serum) ALKALINE PHOSPHATASE (serum)	:	46 99	IU/L IU/L		5 - 40 CHILD BELOW 6 YRS : 60 - 321 CHILD : : 67 - 382 ADULT : : 36 - 113
PROTEINS TOTAL (serum) ALBUMIN (serum) GLOBULIN (serum) A/G RATIO	:	7.0 4.6 2.40 1.92	GM/DL GM/DL GM/DL		6.4 - 8.3 3.5 - 5.7 1.8 - 3.6 1:2 - 2:1

END OF REPORT

Technician

PRITAM WAGHMARE Report Type By :-

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)





PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

: BANK OF BARODA **Company Name**

Reporting Date & Time

: 09/07/2022 02:05 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:11 PM

PARAMETER NAME

RESULT VALUE

UNIT

MG/DL

MG/DL

MG/DL

MG/DL

NORMAL VALUES

BIOCHEMISTRY

LIPID PROFIL	Ε
--------------	---

CHOLESTEROL (serum)	•	131
TRIGLYCERIDE (serum)	:	153
HDL (serum)	:	34
LDL (serum)	:	146
VLDL (serum)	:	30.60
CHOLESTROL/HDL RATIO	:	5.79
LDL/HDL RATIO	:	4.29

Male: 120 - 240 MG/DL Female: 110 - 230

0 - 150

Male:: 42 - 79.5 Female: : 42 - 79.5

0 - 130

5 - 51

Male: 1.0 - 5.0 Female: : 1.0 - 4.5

Male: <= 3.6 Female: <=3.2

NCEP Guidelines

LDL/HDL RATIO

	Desirable	Borderline	Undesirable
Total Cholesterol (mg/dl)	Below 200	200-240	Above 240
HDL Cholesterol (mg/dl)	Above 60	40-59	Below 40
Triglycerides (mg/dl)	Below 150	150-499	Above 500
LDL Cholesterol (mg/dl)	Below 130	130-160	Above 160

Suggested to repeat lipid profile with low fat diet for 2-3 days prior to day of test and abstinence from alcoholic beverages if applicable. Cholesterol & Triglycerides reprocessed , & confirmed.

END OF REPORT

Technician

PRITAM WAGHMARE Report Type By :-

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)





PRN : 081720 Lab No

: 4105

Patient Name

Mr. SARDA KRISHNAKANT

Reg.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

Company Name

: BANK OF BARODA

Reporting Date & Time

: 09/07/2022 02:05 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:11 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

ENDOCRINOLOGY

TFT (THYROID FUNCTION TEST)

0.970 - 1.69ng/mL T3-Total (Tri iodothyronine) 1.49 µg/dL 5.53 - 11.0 T4 - Total (Thyroxin) 9.67 Thyroid Stimulating Hormones (Ultra: µIU/mL 0.465 - 4.681.42

TSH)

NOTE:-

Three common ways in which there may be inadequate amounts of the thyroid harmone for normal metabolism. Primary hypothyroidism, in which there is a raised TSH & a low T3. This is due to failure of the thyroid land, possibly due to autoantibody disease, possibly due to toxic stress or possib due to iodine deficiency. The second, the most common cause of thyroid failure, occurs at the pituitary level. In this condition thre is inadequte thyroid stimulating harmone (TSH) produced from the pituitary and so one tends to see low or normal TSH, low T4s and variable T3s. This condition is most common in many patients with chronic fatigue syndrome, where there is a general suppression of the hypothalamic-pituitary-adrenal axis. The third type of under-functioning is due to poor conversion of there are normal or possibly slightly raised levels of TSH, normal levels of T4 but low levels of thyroid problem routinely TSH, a Free T4 and a Free T3 are also advisable. Any patients who are yaking T3 as part of their thyroid supplement need t have their T3 levels monitored as well as T4. T3 is much more quickly metabolized than T4 and blood tests should be done between 4-6 hours after their morning dose.

The Guideline for pregnancy reference ranges for total T3, T4, Ultra TSH Level in pregnancy

THE CAIGOMIC TO	programoj referen	or ranged for total for	
	Total T3	Total T4	Ultra TSH
First Trimester	0.86 - 1.87	6.60 - 12.4	0.30 - 4.50
2 nd Trimester	1.0 - 2.60	6.60 - 15.5	0.50 - 4.60
3 rd Trimester	1.0 - 2.60	6.60 - 15.5	0.80 - 5.20
The avidelines f	or and related refere	non ranges for T2 T4 0	Liltro TCH

The guidelines for age related reference ranges for T3,T4,& Ultra TSH Total T3 Total T4 Ultra TSH

Birth- 4 day: 1.0-38.9 Cord Blood 0.30 - 0.70 1-3 day 8.2-19.9 2-20 Week: 1.7-9.1 New Born 0.75 - 2.60 1 Week 6.0-15.9 1-5 Years 1.0-2.60 1-12 Months 6.8 - 14.9 20 Week- 20 years 0.7 - 6.4

1-3 Years 6.8-13.5 5-10 Years 0.90 - 2.40 10-15 Years 0.80 - 2.10 3-10 Years 5.5-12.8

END OF REPORT

Dr. POONAM KADAM

MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)

Technician

Report Type By :- PRITAM WAGHMARE





PRN

: 081720

Lab No

: 4105

Patient Name

Mr. SARDA KRISHNAKANT

Req.No

: 4106

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:30 AM

Company Name

: BANK OF BARODA

Reporting Date & Time : 09/07/2022 02:12 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:13 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

SPECIAL TEST

VITAMIN D

25 - HYDROXY VITAMIN D

61.9

ng/mL

Deficient:: <20

Insufficient:: 20 - 30

Sufficient::>30 - 100 Toxicity: >100

NOTE :-

1)Vitamin D is a fat-soluble steroid hormone precursor that is mainly produced in the skin by exposure to sunlight or it is supplied via dietary sources (mainly egg yolk, fish oil and plants).

2) Vatamin D is biologically inert and must undergo two successive hydroylations in the liver and kidney to become the biologically avtive 1,25 dihydroxyvitamin D.

3) The two most importent forms of vitamin D are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol).

4) In contrast to vitamin D3, vatimin D2 has to be taken up with food. In the human body vitamin D3 D2 are bound to vitamin D-binding protein in plasma and transported to the liver where both are hydroxylated in position 25 forming 25- OH vitamin D. 25 OH vitamin D is the metabolite that should be measured in blood to determine the overall vitamin Dstatus because it is the major storage from of vitamin D in human body. 5) This primary circulating from of vitamin D is biologacally inactive with levels approximately 1000-fold greater than the circulating 1,25 (OH)2 vitamin

D. The half life of circulating 25- OH vitamin D is 2-3 weeks. More than 95% of 25-OH vitamin D2 reaches measurable levels only in patients taking

vitamin D2 supplements.

6) Vitamin D deficiency is a common cause of secondary hyperparathyroidism. Elevation of PTH levels, especially in elderly Vitamin D deficient adults can result in osteomalacia, increased bone turnover, reduced bone mass and risk of bone fractures.

7) Low 25-OH vitamin D concentration are also associated with lower bone mineral density. In conjuction with other clinical data, the results may be used as an aid in the assessment of bone metabolism.

8) The Roche Cobas Vitamin D3 (25-OH) assay employs a polyclonal antibody directed against vitamin D3.

END OF REPORT

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology &

Bacteriology (MMC-2012/03/0668)

Technician

Report Type By :- PRITAM WAGHMARE





PRN

: 081720

Lab No

: 4105

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:29 AM

: BANK OF BARODA

Reporting Date & Time

: 09/07/2022 02:05 PM

Referred By

Company Name

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:11 PM

PARAMETER NAME

RESULT VALUE

UNIT

ML

NORMAL VALUES

CLINICAL PATHOLOGY

URINE ROUTINE

PHYSICAL EXAMINATION

QUANTITY

25

COLOUR **APPEARANCE** PALE YELLOW SLIGHTLY HAZY

REACTION

NEUTRAL

SPECIFIC GRAVITY

1.005

CHEMICAL EXAMINATION

PROTEIN . **ABSENT** SUGAR **ABSENT KETONES ABSENT BILE SALTS ABSENT BILE PIGMENTS**

UROBILINOGEN

ABSENT NORMAL

MICROSCOPIC EXAMINATION

PUS CELLS 0-1 /hpf **RBC CELLS ABSENT** / hpf **EPITHELIAL CELLS** 0-1 /hpf **CASTS ABSENT** /hpf

CRYSTALS ABSENT OTHER FINDINGS **ABSENT BACTERIA ABSENT**

END OF REPORT

Technician

Report Type By :-PRITAM WAGHMARE

Dr. POONAM KADAM MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)





PRN

: 081720

Lab No

Patient Name

: Mr. SARDA KRISHNAKANT

Req.No

: 4105 : 4106

Age/Sex

: 36Yr(s)/Male

Collection Date & Time: 09/07/2022 10:30 AM

Company Name

: BANK OF BARODA

Reporting Date & Time : 09/07/2022 02:12 PM

Referred By

: Dr.HOSPITAL PATIENT

Print Date & Time

: 09/07/2022 02:12 PM

PARAMETER NAME

RESULT VALUE

UNIT

NORMAL VALUES

IMMUNOLOGY

VITAMIN B12

VITAMIN B12 LEVEL

491

pg/mL

239 - 931

NOTE:

1) Nutritional and macrocytic anemias can be caused by a deficiency of Vitamin B12. This deficiency can result from diets devoid of meat and bacteria products, from alcoholism, or from structural/functional damage to digestive or absorptive processes (forms of pernicious anemia). Malabsorption is the major cause of this deficiency, gastric atrophy or gastrectomy, intestinal damage, loss of intestinal damage, loss of intestinal Vitamin B12 binding protien (intrinsic factor), production of autoantibodies directed against intrinsic factor, or related causes.

2) This vitamin is necessary for normal metabolism, DNA synthesis and red blood cell regeneration. Untreated deficiencies will lead to megaloblastic

anemia and Vitamin B12 deficiency results in irreversible central nervous system degeneration.

3) Vitamin B12 or folate are both of diagnostic importance for the recognition of Vitamin B12 or folate deficiency, especially in the context of the differential diagnosis of megaloblastic anemia. Redioassays were first reported for Vitamin B12 in 1961. All utilize co-cynocobalamin radiolabeled tracers and intrinsic factor for binding Vitamin B12.

4) The various commercial assays differ in their free versus bound seperation techniques and choice of specimen prereatment. The presence of endogenous serum binding protiens for cyanocobalamin (transcobalamin including R- protien) and of immunoglobulins directed against intrinsic factor

require that specimen are either boiled at an alkaline pH to release the Vitamin B12 and destroy the binding protiens.

5) In the late 1970s, radioassays using serum binding protiens or partially purified intrinsic factor measured levels of Vitamin B12 which exceeded those determined by microbiological methods. This was caused by the presence of the serum binding protien or R-protiens in the assay. 6) R-protien specificity is poor compared to that of intrinsic factor measured in addition to Vitamin B12 analogs were being measured in addition to Vitamin B12 itself. Since that time, recommendations have been established for the use of highly purified intrinsic factor throughout the industry. 7) Roche Cobase Vitamin B12 employs a competitive test principle using intrinsic factor specific for Vitamin B12. Vitamin B12 in the sample using

competes with the added Vitamin B12 labeled with biotin for the binding sites on the ruthenium-labeled intrinsic factor complex**.

END OF REPORT

Dr. POONAM KADAM

MD (Microbiology), Dip.Pathology & Bacteriology (MMC-2012/03/0668)

Technician

Report Type By :- PRITAM WAGHMARE



Dept. of Radiology



REQ. DATE

: 09-JUL-2022

REP. DATE: 09-JUL-2022

NAME

: MR. SARDA KRISHNAKANT PATIENT CODE : 081720

AGE/SEX: 36 YR(S) / MALE

REFERRAL BY : HOSPITAL PATIENT

USG ABDOMEN AND PELVIS

OBSERVATION:

Liver: Is normal in size (13.6 cm), shape & bright in echotexture. No focal lesion / IHBR dilatation.

CBD & PV : Normal in caliber.

G.B.: Moderately distended, Normal.

Spleen: Is normal in size (8.1 cm), shape & echotexture. No focal lesion.

Pancreas: Normal in size, shape & echotexture.

Both kidneys are normal in size, shape & echotexture, CMD maintained.

No calculus/ hydronephrosis / hydroureter on either side.

Partially exophytic simple cyst is noted in the mid pole region of right kidney measuring $3.7 \times 3.0 \text{ cms}$.

Small simple cortical cyst is noted in the upper pole region of left kidney measuring 1.5 x 1.1 cm.

Right kidney measures: 10.1 x 4.8 cm. Left kidney measures : 9.5 x 4.4 cm.

Urinary bladder: Moderately distended, normal.

Prostate: is normal in size, shape and echotexture. No focal lesion seen.

No demonstrable small bowel / RIF pathology.

No ascites / lymphadenopathy.

IMPRESSION:

Grade I fatty liver.

- Kindly correlate clinically.

Dr. PIYUSH YEOLE (MBBS, DMRE)

CONSULTANT RADIOLOGIST



(For Report Purpose Only)



REQ. DATE

: 09-JUL-2022

REP. DATE: 09-JUL-2022

NAME

: MR. SARDA KRISHNAKANT

PATIENT CODE : 081720

AGE/SEX: 36 YR(S) / MALE

REFERRAL BY : HOSPITAL PATIENT

CHEST X-RAY PA VIEW

OBSERVATION:

Prominent bronchovascular markings are noted in both lung fields.

Heart and mediastinum are normal.

Diaphragm and both CP angles are normal.

Visualised bones & extra-thoracic soft tissues appear normal.

IMPRESSION:

Prominent bronchovascular markings in both lung fields? bronchitis.

-Kindly correlate clinically.

Dr. PIYUSH YEOLE (MBBS, DMRE)

CONSULTANT RADIOLOGIST





2D ECHO / COLOUR DOPPLER

NAME: MR. KRISHNAKANT SARDA

37yrs/M

OPD

REF BY: DR. HOSPITAL PATIENT

9-Jul-22

M - Mode values

Doppler Values

AORTIC ROOT (mm)	22	PULMONARY VEL (m/sec)	
LEFT ATRIUM (mm)	28	PG (mmHg)	
RV (mm)		AORTIC VEL (m/sec)	1.2
LVID – D (mm) LVID – S (mm)	41	PG (mmHg)	6
IVS – D (mm)	21	MITRAL E VEL (m/sec)	0.9
LVPW –D (mm)	10	A VEL (m/ sec)	0.6
EJECTION FRACTION (%)	9	TRICUSPID VEL. (m/sec)	
ORT	60%	PG (mmHg)	

REPORT

Normal LV size & wall thickness. No regional wall motion abnormality Normal LV systolic function, LVEF 60% Normal sized cardiac chambers.

Pliable mitral valve., no Mitral regurgitation. Normal mitral diastolic flows.

Trileaflet aortic valve. No aortic stenosis / regurgitation.

Normal Tricuspid & pulmonary valve Trivial tricuspid regurgitation, PA pressure = 20 mmHg - normal

Intact IAS & IVS
No PDA, coarctation of aorta.
No clots, vegetations, pericardial effusion noted.

IMPRESSION:

Normal echo study.
No regional wall motion abnormality.
Normal LV systolic & diastolic function, LVEF 60%
Normal PA pressure.

DR. RAJDATT DEORE. MD, DM-CARDIOLOGIST MMC 2005/03/1520